Fluorine-focused Scifluor Life Sciences Inc. pulled down $30 million that should "allow us to get into what we suspect will be four phase I trials" with a pair of compounds – including eye drops for age-related macular degeneration (AMD) – and provides "at least a two-year runway," CEO Omar Amirana told BioWorld Today.